MX2022005676A - Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos. - Google Patents

Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.

Info

Publication number
MX2022005676A
MX2022005676A MX2022005676A MX2022005676A MX2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A
Authority
MX
Mexico
Prior art keywords
methods
polypeptides
making
releasable
barcoded
Prior art date
Application number
MX2022005676A
Other languages
English (en)
Inventor
Volker Schellenberger
Eric Johansen
Angela Henkensiefken
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Publication of MX2022005676A publication Critical patent/MX2022005676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

En la presente descripción se describen polipéptidos que comprenden un polipéptido recombinante extendido (XTEN) compuesto por una pluralidad de motivos de secuencia superpuestos y uno o más fragmentos de código de barras liberables tras la digestión con proteasa y detectables a partir de todos los demás fragmentos liberables proteolíticamente. Ciertas modalidades de estos polipéptidos comprenden además un polipéptido biológicamente activo, en donde modalidades ventajosas de este comprenden un segmento liberable capaz de escisión proteolítica que escinde el enlace entre el polipéptido XTEN y el polipéptido biológicamente activo. También se describen métodos de preparación y métodos de uso de dichos polipéptidos.
MX2022005676A 2019-11-13 2020-11-13 Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos. MX2022005676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934980P 2019-11-13 2019-11-13
PCT/US2020/060378 WO2021097186A1 (en) 2019-11-13 2020-11-13 Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Publications (1)

Publication Number Publication Date
MX2022005676A true MX2022005676A (es) 2022-10-27

Family

ID=73740585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005676A MX2022005676A (es) 2019-11-13 2020-11-13 Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.

Country Status (12)

Country Link
US (1) US20230287040A1 (es)
EP (1) EP4058466A1 (es)
JP (1) JP2023501478A (es)
KR (1) KR20220131221A (es)
CN (1) CN115175920A (es)
AU (1) AU2020382621A1 (es)
BR (1) BR112022009217A2 (es)
CA (1) CA3157605A1 (es)
CO (1) CO2022008004A2 (es)
IL (1) IL292863A (es)
MX (1) MX2022005676A (es)
WO (1) WO2021097186A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175933A (zh) * 2019-06-26 2022-10-11 阿穆尼克斯制药公司 Cd3抗原结合片段和包含其的组合物
JP2023531494A (ja) * 2020-06-25 2023-07-24 アムニクス ファーマシューティカルズ， インコーポレイテッド Ｈｅｒ－２標的化二重特異性組成物ならびにその作製および使用のための方法
CA3238167A1 (en) * 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5374618A (en) 1983-06-15 1994-12-20 Celltech Limited Calcitonin peptides, and gene related pharmaceutical compositions
DK27885A (da) 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
IE66689B1 (en) 1985-09-12 1996-01-24 Scios Nova Inc Recombinant fibroblast growth factors
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5631230A (en) 1989-09-21 1997-05-20 Arizona Technology Development Corporation Receptor selective analogues of cholecystokinin-8
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5364840A (en) 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
CA2090969C (en) 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH08510205A (ja) 1993-03-29 1996-10-29 ユニバーシティ オブ シンシナティ Ｙｙペプチドのアナログとその用途
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US6214797B1 (en) 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
EP0845036B1 (en) 1995-08-18 1999-06-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
DE60029572T2 (de) * 1999-03-23 2007-07-26 Biovation Ltd. Isolierung und analyse von proteinen
CN100506844C (zh) 1999-07-23 2009-07-01 寒川贤治 新的肽
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
JP2004514651A (ja) 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
WO2004048547A2 (en) 2002-11-26 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
HUE039154T2 (hu) 2003-03-03 2018-12-28 Dyax Corp HGF receptort (cMet) specifikusan kötõ peptidek és alkalmazásaik
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
BRPI0615745A2 (pt) 2005-09-12 2011-05-24 Novimmune Sa formulação de anticorpo anti-cd3
KR102274003B1 (ko) 2007-01-19 2021-07-08 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
CA2738545A1 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
MX354555B (es) 2009-06-08 2018-03-09 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
LT2882450T (lt) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20180125988A1 (en) * 2014-11-11 2018-05-10 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure
JP6558679B2 (ja) 2015-04-24 2019-08-14 パナソニックＩｐマネジメント株式会社 点灯装置、照明装置及び照明器具
US11339434B2 (en) * 2016-07-29 2022-05-24 The Regents Of The University Of California Methods for determining gene functions
BR112020012220A2 (pt) * 2017-12-21 2021-01-26 Amunix Pharmaceuticals, Inc. segmentos de liberação e composições de ligação que compreende os mesmos

Also Published As

Publication number Publication date
CO2022008004A2 (es) 2022-10-21
CN115175920A (zh) 2022-10-11
KR20220131221A (ko) 2022-09-27
JP2023501478A (ja) 2023-01-18
EP4058466A1 (en) 2022-09-21
CA3157605A1 (en) 2021-05-20
AU2020382621A1 (en) 2022-06-02
BR112022009217A2 (pt) 2022-08-02
US20230287040A1 (en) 2023-09-14
WO2021097186A1 (en) 2021-05-20
IL292863A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
MX2022005676A (es) Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.
EP4321530A3 (en) Masked cytokine polypeptides
ES2723774T3 (es) Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
MX2021003261A (es) Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
ATE350470T1 (de) Durch thrombin spaltbare chimäre proteine
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
EP3981428A4 (en) PROTEAS SUBSTRATE AND POLYPEPTIDE WITH PROTEAS CLEAVAGE SEQUENCE
AR118443A1 (es) Proteínas de fusión, bacterias recombinantes y fragmentos de exosporas para control de plagas y salud de las plantas
MX2022014167A (es) Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada.
PH12021550789A1 (en) Disulfide bond stabilized polypeptide compositions and methods of use
CR20230178A (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
MX2020005670A (es) Variantes de expresión de cdkl5 y proteínas de fusión de cdkl5.
MX2022008073A (es) Anticuerpos dirigidos a los huesos.
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
WO2006071250A3 (en) Soluble fragments of the sars-cov spike glycoprotein
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
DE60118935D1 (de) Dna & protein bindende miniatur proteine
DE60313743D1 (de) Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen
MX2009009370A (es) Conjugados del complemento de peptido.
WO2019046446A3 (en) COMPOSITIONS AND METHODS USING METHANOTROPHE LAYER PROTEINS FOR THE EXPRESSION OF HETEROLOGOUS PROTEINS